Strongbridge Biopharma plc
NASDAQ: SBBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Pauls
- Employees
- 72
- Headquarters
- Trevose, United States
- IPO year
- 2015
- Website
- http://www.strongbridgebio.com
Loading SBBP…
Loading profile data…Frequently asked questions about SBBP
What does Strongbridge Biopharma plc (SBBP) do?
Strongbridge Biopharma plc is a biopharmaceutical firm actively engaged in both creating and marketing treatments for rare conditions where patient needs are currently not met. As a commercial-stage entity, its portfolio includes Keveyis, an orally administered carbonic anhydrase inhibitor approved in the United States for addressing hyperkalemi...
Where does SBBP trade?
Strongbridge Biopharma plc (SBBP) trades on the NASDAQ Global Select.
What sector is SBBP in?
Strongbridge Biopharma plc (SBBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Strongbridge Biopharma plc?
Matthew Pauls is the chief executive officer of Strongbridge Biopharma plc (SBBP).
Where is Strongbridge Biopharma plc headquartered?
Strongbridge Biopharma plc is headquartered in United States.
Does SBBP pay a dividend?
Strongbridge Biopharma plc (SBBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SBBP go public?
Strongbridge Biopharma plc (SBBP) completed its initial public offering in 2015.